Salarius Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: DCOY · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1615219
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
Related Tickers: SLRX
TL;DR
Salarius Pharma (SLRX) filed an 8-K on shareholder vote matters. Keep an eye on the outcome.
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K on December 23, 2024, reporting on matters submitted to a vote of security holders as of December 20, 2024. The filing indicates a change in the company's reporting status or a significant corporate event requiring disclosure.
Why It Matters
This filing is important as it signals a potential corporate action or decision that has been put to a vote by Salarius Pharmaceuticals' shareholders, which could impact the company's future direction.
Risk Assessment
Risk Level: medium — Filings related to shareholder votes can indicate significant corporate events or changes that may carry inherent risks.
Key Numbers
- 001-36812 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5087339 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- December 20, 2024 (date) — Date of earliest event reported
- December 23, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 2450 Holcombe Blvd. Suite X (address) — Principal executive offices
- Houston, TX 77021 (address) — Principal executive offices
- Flex Pharma, Inc. (company) — Former company name
FAQ
What specific matters were submitted to a vote of Salarius Pharmaceuticals' security holders?
The filing does not specify the exact matters submitted to a vote, only that it is reporting on 'Submission of Matters to a Vote of Security Holders'.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 20, 2024.
What is the principal executive office address for Salarius Pharmaceuticals, Inc.?
The principal executive office is located at 2450 Holcombe Blvd. Suite X, Houston, TX 77021.
What was Salarius Pharmaceuticals, Inc. formerly known as?
The company was formerly known as Flex Pharma, Inc.
In which state was Salarius Pharmaceuticals, Inc. incorporated?
Salarius Pharmaceuticals, Inc. was incorporated in Delaware.
Filing Stats: 649 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-12-23 12:22:37
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
Filing Documents
- flks-20241220.htm (8-K) — 41KB
- 0001615219-24-000101.txt ( ) — 161KB
- flks-20241220.xsd (EX-101.SCH) — 2KB
- flks-20241220_lab.xml (EX-101.LAB) — 21KB
- flks-20241220_pre.xml (EX-101.PRE) — 12KB
- flks-20241220_htm.xml (XML) — 3KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders On December 20, 2024, Salarius Pharmaceuticals, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of October 25, 2024, the record date for the Annual Meeting, there were 1,441,157 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 572,540, or 39.7%, were present in person or represented by proxy, which constituted a quorum. At the Annual Meeting, the stockholders voted and: (1) re-elected each of the Company's two nominees for Class III director; (2) approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting; and (3) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting. Proposal 1. To elect two Class III directors to serve until the 2027 annual meeting or until their successors are duly elected and qualified: Nominees Votes For Votes Against Abstentions Broker Non-Votes Tess Burleson 141,974 12,711 2,127 415,728 Paul Lammers 145,485 9,196 2,131 415,728 Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting: Votes For Votes Against Abstentions Broker Non-Votes 135,949 18,637 2,226 415,728 Proposal 3. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: Votes For Votes Against Abstentions 496,239 59,576 16,725
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: December 23, 2024 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Executive Vice President & Chief Financial Officer